Research Interest: Host virus Interactions, Immune resistance, steroids

Research Interest: Tumor immunology and Cancer immunotherapy

Research Interest:  Nanomaterial platforms for safe and effective delivery of biomacromolecules and drugs for cancer treatment

Research Interest: Immunotherapy for brain tumors; development of a DNA vaccine for treatment of brain tumors; passive immunotherapy for treatment of Alzheimers disease

Research Interest: Epigenetics, Tumor Immunology

Research Interest: Medical Practice related clinical studies.

Research Interest: Oral Precancer, Free flaps, Head and Neck Reconstruction, Post Surgical functional outcomes 

Research Interest: Cancer research, Epigenetics in cancer, Lung carcinoma, Apoptosis, Hypoxia

Research Interest: Drug Testing, Proteomics, Genomics, Translational Research

Research Interest: Protein Biochemistry, Translational research, Metastasis, Cancer research, Oncology

Research Interest: Cancer Immunotherapy; T cell/Tumor Cell signaling

Research Interest: Paediatrics, Paediatric Nursing

Research Interest: Inflammation, Inflammatory Diseases, Immune response, Immunopharmacology

Research Interest: Sensorymotor transformation, Mechanisms involved in the control of posture, Vestibular system, Electophysiology in vivo, Study of vestibular reflex in humans, Synaptic plasticity, Effects of antidepressants on CNS, Serotonin, Noradrenaline and glutamate receptors

Research Interest: Electrophysiology - Glutamatergic System - Serotoninergic System - Noradrenergic System - Control of Movement and Posture - Human Stabilometry - Vestibular Reflex - Cerebellar and Vestibular System.

Research Interest: Carbohydrates, Natural Products, Synthesis

Research Interest: Cancer chemotherapy- Cell death- Cancer Stem cell- Experimental cancer therapy

Research Interest: Oral cancer oral mucosa 

Research Interest:  Antibodies; Immunotechnology; human invasive carcinomas

Research Interest: Biomaterials, medical devices, new techniques, preclinical trials and imaging diagnosis in laparoscopic, endoscopic and other minimally invasive procedures and surgical technologies.

Research Interest: Animal and Cell cultura modela Of Liver fibrosis and c�ncer

Research Interest: Chemical Carcinogenesis, Inflammation & cancer, Fibrosis and cancer, Cell cycle, Signal transduction

Research Interest: (1) Gastroenterology and hepatobiliary diseases (2) Hepatitis and hepatoma (3) The molecular mechanisms of hepatocellular carcinogenesis using the molecular and cellular biology, genomics and proteomics approaches.

Research Interest: Bioimaging, nanomaterials, fluorescence detection

Research Interest: "Molecular Embryology Stem cells Reproductive Toxicology Teratology "

Research Interest: Gram negatives, antibiotic stewardship, antibiotic prophylaxis

2015 – PhD, University of Cambridge, UK

2010 – MPhil, Newcastle University, UK

Research Interest: Molecular and cell biology, immunology, oncology

Grants: Russian Foundation of Basic Research
(#16-34-60213; #16-34-50250; #17-34-50167; # 19-54-10005)

URL: https://kpfu.ru/emil.bulatov?p_lang=2

List of Publications:

Articles and conference abstracts

(2018) Article.
1. Emil Bulatov, Regina Sayarova, Rimma Mingaleeva, Regina Miftakhova, Marina Gomzikova, Yuri Ignatyev, Alexey Petukhov, Pavel Davidovich, Albert Rizvanov and Nickolai Barlev / Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors // Cell Death Discovery, 4: 103 (2018)
DOI: 10.1038/s41420-018-0120-z
https://www.nature.com/articles/s41420-018-0120-z

(2018) Quartile Q1. Article.
2. Aleksei Titov, Alexey Petukhov, Alena Staliarova, Dmitriy Motorin, Emil Bulatov, Oleg Shuvalov, Surinder M. Soond, Mauro Piacentini, Gerry Melino, Andrey Zaritskey & Nickolai A. Barlev. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites // Cell Death & Disease, 9, Article: 897 (2018)
Impact Factor = 6.187
DOI: 10.1038/s41419-018-0918-x
https://www.nature.com/articles/s41419-018-0918-x

(2018) Quartile Q2. Article.
3. Emil Bulatov, Aygul Valiullina, Regina Sayarova, Albert Rizvanov. Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases. Immunology Letters, 2018, 202, 44-51.
Impact Factor = 2.664 
DOI: 10.1016/j.imlet.2018.08.001
https://www.sciencedirect.com/science/article/pii/S0165247817306077

(2018) Quartile Q1. Article.
4. Bulatov E, Zagidullin A, Valiullina A, Sayarova R, Rizvanov A. Small molecule modulators of RING-type E3 ligases: MDM and cullin families as targets // Frontiers in Pharmacology, 2018, 9, Article 450.
Impact Factor = 4.439
DOI: 10.3389/fphar.2018.00450
https://www.frontiersin.org/articles/10.3389/fphar.2018.00450/full
WOS:000431660700001

(2018) Quartile Q1. Article.
5. Vafina, G., Zainutdinova, E., Bulatov, E., Filimonova, M.N. Endonuclease from gram-negative bacteria Serratia marcescens is as effective as pulmozyme in the hydrolysis of DNA in sputum. // Frontiers in Pharmacology, 2018, 9,  Article 114.
Impact Factor  = 4.439
DOI: 10.3389/fphar.2018.00114
https://www.frontiersin.org/articles/10.3389/fphar.2018.00114/full
WOS:000425298100001

(2018)
Monography (27 pages).
6. Emil Bulatov. E3 ubiquitin ligases as targets for small molecule drug discovery: focus on Cullin RING family.
Глава в книге "Ubiquitin Proteasome System: A Review and Directions for Research". Hardcover edited collection (by selected invitation only). Nova Science Publishers, Inc., USA.
https://www.novapublishers.com/catalog/product_info.php?products_id=64423

(2018) Quartile Q2. Conference thesis.
7. Glagoleva, I., Kudriaeva, A., Belogurov, A., Rizvanov, A. and Bulatov, E. / Effect of Nutlin-3a, RG-7112, Carfilzomib and MG-132 on accumulation of p53 in eukaryotic HEK293 cell line // European Journal of Clinical Investigation, 2018, 48, 100
Impact Factor = 2.707
WOS:000434100200222
DOI: 10.1111/eci.12926

(2017) Quartile Q1. Conference thesis.
8. A. Valiullina, M. Gomzikova, T. Khaibullin, A. Rizvanov & E. Bulatov. Regulation of p53-dependent genes expression in multiple sclerosis: the effect of MDM2 inhibitor Nutlin-3a. // European Journal of Clinical Investigation, 2017, 47 (Suppl. 1), 141–142
Impact Factor = 2.714
DOI: 10.1111/eci.12749
https://kpfu.ru//staff_files/F1836875316/ESCI_141_142.pdf
WOS:000412099900326

(2017) Quartile Q1. Conference thesis.
9. Aygul Kh. Valiullina, Marina Gomzikova, Ekaterina E. Garanina, Timur Khaibullin, Albert Rizvanov, and Emil Bulatov. Small Molecule p53-MDM2 Inhibitors As Potential Regulators of p53-Dependent Genes Expression in Multiple Sclerosis. // Blood, 2017, 130:4820
Impact Factor = 13.164
http://www.bloodjournal.org/content/130/Suppl_1/4820

(2017) Quartile Q2. Conference thesis.
10. A. Valiullina, M. Gomzikova, T. Khaibullin, E. Garanina, E. Zmievskaya, A. Rizvanov, E. Bulatov. Effect of p53 activation on target gene expression and cytokine release in peripheral blood mononuclear cells. // Mol. Biol. Cell, 2017, vol. 28, no. 26, 545-546
Impact Factor = 3.685
DOI: 10.1091/mbc.E17-10-0618
https://kpfu.ru//staff_files/F_1215039000/2017ASCB_545_546.pdf

(2016) Quartile Q2. Conference thesis.
11. Валиуллина, А.Х., Саярова, Р.М., Соловьева, В.В., Ризванов, А.А., Булатов Э.Р. Изучение роли белков р53 и MDM2 в качестве потенциальных регуляторов аутоиммунных процессов при рассеянном склерозе. // Acta Naturae, 2016, спецвыпуск, том 2, с. 66
Impact Factor = 1.770
http://kpfu.ru//staff_files/F1913808647/2016_ActaNaturae_66.pdf

(2016) Quartile Q3. Article.
12. Vafina G, Bulatov E, Zaynutdinova E, Filimonova M. A One-Step Protocol for Chromatographic Purification of Non-recombinant Exogenous Bacterial Enzyme: Nuclease of Serratia marcescens // BioNanoScience. - 2016. - Vol.6, Is.4. - P.335-337.
CiteScore (Scopus) = 1.48
DOI: 10.1007/s12668-016-0226-9
https://link.springer.com/article/10.1007/s12668-016-0226-9
WOS:000390587700015

(2016) Quartile Q3. Article.
13. Bulatov, E., Khaiboullina, S, dos Reis, H.J., Palotás, A., Venkataraman, K., Vijayalakshmi, M., Rizvanov, A. Ubiquitin-Proteasome System: Promising Therapeutic Targets in Autoimmune and Neurodegenerative Diseases // BioNanoScience. - 2016. - Vol.6, Is.4. - P.341-344.
CiteScore (Scopus) = 1.48
DOI: 10.1007/s12668-016-0233-x
https://link.springer.com/article/10.1007/s12668-016-0233-x
WOS:000390587700017

(2016) Quartile Q2. Conference thesis.
14. P. Davidovich, R. Sayarova, A. Valiullina, V. Solovyeva, M. Gomzikova, A. Smirnov, A. Rizvanov,
E. Bulatov. Novel isatin-Schiff base copper (II) complexes as potential p53-activating pro-apoptotic agents. // Mol. Biol. Cell, 2016, 27:25, 3947, 708.
Impact Factor = 4.037
DOI: 10.1091/mbc.E16-10-0736
http://www.molbiolcell.org/content/suppl/2016/12/08/27.25.3947.DC1/2016ASCBMeeting-PosterAbstracts.pdf
WOS:000396047100121

(2016) Quartile Q1. Conference thesis.
15. Bulatov E., Valiullina A., Sayarova R., Rizvanov A. Inhibitors of MDM2 ubiquitin ligase as prospective modulators of autoimmunity // FEBS JOURNAL. - 2016. - Vol.283, Is.. - P.360-360.
Impact Factor = 4.237
DOI: 10.1111/febs.13808
http://onlinelibrary.wiley.com/doi/10.1111/febs.13808/epdf
WOS:000383616901715

(2015) Quartile Q1. Article.
16. Gadd, M. S., Bulatov, E. and Ciulli, A. Serendipitous SAD Solution for DMSO-Soaked SOCS2-ElonginC-ElonginB Crystals Using Covalently Incorporated Dimethylarsenic: Insights into Substrate Receptor Conformational Flexibility in Cullin RING Ligases. // PLoS ONE 2015, 10, e0131218.
Impact Factor = 3.234
DOI: 10.1371/journal.pone.0131218
WOS:000358150400086

(2015) Quartile Q1. Article.
17. Bulatov, E. and Ciulli, A. Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. // Biochem. J. 2015, 467, 365–386.
Impact Factor = 3.85
DOI: 10.1042/BJ20141450
WOS:000353217200002

(2015) Quartile Q1. Article.
18. Bulatov, E., Martin, E. M., Chatterjee, S., Knebel, A., Shimamura, S., Konijnenberg, A., Johnson, C., Zinn, N., Grandi, P., Sobott, F., Ciulli, A. Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2). // J. Biol. Chem. 2015, 290, 4178–4191.
Impact Factor 2014 = 4.253
DOI: 10.1074/jbc.M114.616664
Article recommended by F1000Prime in Technical Advance category
WOS:000349458400029